統合失調症におけるパリペリドンパルミテート維持療法に関連した血タンパク質パターン:前向きなコホート研究
Weiwei Zeng1, Feiqing Liang1, Xiaoying Lin1
1Department of Pharmacy, Shenzhen Longgang Second People's Hospital, Shenzhen, Guangdong, China.
CNS drugs
|August 29, 2025
まとめ
この研究では,パリペリドンパルミテート注射で治療された統合失調症患者の血タンパク質の変化が確認されました. これらのプロテオミックシグネチャーは,治療反応を予測し,治療の有効性を監視するのに役立ちます.
科学分野:
- 精神医学 と 神経科学
- プロテオミクス
- ファルマゲノミクス
背景:
- 統合失調症の治療への反応は個人に大きく異なっています.
- 長期作用の注射用パリペリドンパルミテート (PP1M) は,アデバーンスを改善しますが,すべての患者にとって最適な結果を保証するものではありません.
- 長期作用の注射薬の有効性の変動は,血タンパク質発現の変化と関連している可能性があります.
研究 の 目的:
- PP1M 治療に対する個々の反応の違いと 血タンパク質濃度の変化の相関を調査する.
- 統合失調症患者のPP1M治療に関連するプロテオミクシグネチャーを特定する.
主な方法:
- 中国の深で実施された前向きなコホート研究.
- Olink Proximity Extension Assay (PEA) プロテオミクス技術は,プラズマサンプルを分析するために使用されています.
- 28人の統合失調症患者 (PP1M治療前のおよび後の) と27人の健康な対照群で血タンパク質濃度を測定した.
主要な成果:
- PP1M治療は臨床症状が持続/改善したが,プロラクチン濃度が上昇した.
- 統合失調症患者と対照群を区別する25の血タンパク質を特定した.
- 4つの異なるタンパク質発現パターンを発見し,PP1M治療後の健康レベルへの回復を示す特定のタンパク質 (例えば,ENO2,QDPR,ANXA11) を特定した.
- PP1M誘発の高血糖症に関連した,初期タンパク質マーカー (ANXA11,DIABLO,CLEC5A) を特定した.
結論:
- 統合失調症における 変異に関連したプロテオミクシグネチャー
- これらのタンパク質マーカーはサブグループ層化に役立ちます.
- PP1M治療中の薬動学的シフトをモニタリングするための治療に伴うコンパニオンバイオマーカーとして潜在的な使用.
関連する概念動画
Psychosis and Antipsychotic Drugs: Overview
453
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
453
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Mania and Antimanic Drugs: Overview
318
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
318
Drug Distribution: Plasma Protein Binding
6.6K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
6.6K
Drug Therapy
96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
96
Antipsychotic Drugs: Typical and Atypical Agents
313
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
313


